Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRE 
Prenetics Global Ltd (PRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: PRE (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.82% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.45M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.15 | 52 Weeks Range 3.09 - 11.99 | Updated Date 08/30/2025 |
52 Weeks Range 3.09 - 11.99 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45875764 | Price to Sales(TTM) 2.32 |
Enterprise Value 45875764 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 1.1 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 11453000 | Shares Floating 9154745 |
Shares Outstanding 11453000 | Shares Floating 9154745 | ||
Percent Insiders 19.88 | Percent Institutions 12.67 |
Upturn AI SWOT
Prenetics Global Ltd
Company Overview
History and Background
Prenetics Global Ltd is a global diagnostics and genetic testing company. While detailed founding year and early milestones are not always readily available, it has grown through strategic acquisitions and partnerships. The company focuses on personalized healthcare through advanced diagnostics.
Core Business Areas
- Genetic Testing: Provides a range of genetic testing services for disease risk prediction, personalized medicine, and family planning.
- Early Cancer Detection: Offers early-stage cancer screening tests using advanced liquid biopsy technology.
- COVID-19 Testing: Initially prominent during the pandemic, providing rapid and accurate COVID-19 testing solutions.
Leadership and Structure
Specific details on the leadership team and organizational structure are not always widely publicized, but it generally comprises experienced executives in healthcare, biotechnology, and finance.
Top Products and Market Share
Key Offerings
- CircleDNA: A comprehensive at-home DNA test kit providing insights into health risks, ancestry, and personalized wellness. Competitors include 23andMe (ME) and AncestryDNA (private). Market share data is fragmented across the broader consumer genomics market. Revenue data is not publicly disaggregated.
- ColoClear by Circle: Non-invasive stool DNA test for colorectal cancer screening. Competitors include Exact Sciences (EXAS) with Cologuard. Market share data is not publicly available, as it's a newer entrant. Revenue figures are bundled within Prenetics' overall diagnostics revenue.
- COVID-19 Testing Solutions: Provided rapid PCR and antigen testing during the pandemic. Competitors included Abbott Laboratories (ABT) and Roche (ROG.SW). Market share has significantly declined as the pandemic has subsided. Revenue substantially decreased post-pandemic.
Market Dynamics
Industry Overview
The diagnostics and genetic testing industry is experiencing rapid growth, driven by advancements in technology, increasing awareness of personalized medicine, and rising healthcare expenditure.
Positioning
Prenetics aims to be a leader in personalized healthcare solutions, focusing on early disease detection and genetic insights. Its competitive advantages include its comprehensive testing portfolio and strategic partnerships.
Total Addressable Market (TAM)
The global genetic testing market is estimated to reach hundreds of billions of dollars. Prenetics is positioned to capture a share of this TAM through its diverse product offerings and geographic expansion. However, more specific numbers and TAM positioning not currently avalable.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Strong focus on innovation
- Strategic partnerships
- Experienced management team
- Global presence
Weaknesses
- Limited profitability
- High operating costs
- Dependence on key partnerships
- Relatively new to market in certain segments
- High marketing spend
Opportunities
- Expanding market for genetic testing
- Increasing adoption of personalized medicine
- Growing demand for early disease detection
- Potential for strategic acquisitions
- Geographic expansion
Threats
- Intense competition
- Regulatory changes
- Pricing pressure
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- EXAS
- ME
- ILMN
- TMO
Competitive Landscape
Prenetics faces stiff competition from established players with greater resources. However, its innovative products and strategic partnerships give it a competitive edge in specific segments.
Major Acquisitions
Insighta
- Year: 2024
- Acquisition Price (USD millions): 10
- Strategic Rationale: Expands precision oncology portfolio with cutting edge AI technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been fueled by increasing demand for genetic testing and early disease detection, as well as strategic acquisitions. Specifics data unavailable.
Future Projections: Future growth is expected to be driven by further expansion into new markets, continued product innovation, and strategic partnerships. Specific analyst estimates would be needed.
Recent Initiatives: Recent initiatives may include the launch of new products, expansion into new geographic markets, or strategic acquisitions.
Summary
Prenetics Global Ltd is a growing player in the personalized healthcare market, driven by its comprehensive product portfolio and strategic partnerships. While it faces strong competition and profitability challenges, its focus on innovation and expansion provides significant growth opportunities. Successful execution of its strategic initiatives is crucial for achieving sustainable profitability and long-term success. Monitoring industry trends and regulatory changes will be essential for mitigating potential threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Press releases
- Analyst estimates (where available)
- Other publicly available information
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market data can change rapidly. The market share percentages are approximate and can fluctuate. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Global Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.